{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-009936","form_type":"8-K","ticker":"NSPR","cik":"0001433607","company_name":"InspireMD, Inc.","filed_at":"2025-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.615196+00:00","generated_at":"2026-05-24T22:14:20.968229+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"InspireMD Q4 net loss widens to $9.2M; revenue up 11%; FDA approval for CGuard Prime expected H1 2025","bullets":["Q4 revenue rose 10.7% YoY to $1.95M; gross profit fell 7.1% to $469K as COGS grew faster.","Net loss widened to $9.17M ($0.19/sh) from $5.41M ($0.16/sh); operating expenses surged 56% to $9.84M.","Full-year 2024 revenue $7.01M (+13% YoY); net loss $32.0M ($0.76/sh) vs $19.9M ($0.82/sh).","Cash and marketable securities $34.6M at Dec 31, 2024, down from $39.0M a year earlier.","Submitted PMA to FDA for CGuard Prime; enrolled first patients in CGUARDIANS II TCAR study; expects US approval H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-009936","json":"https://secwatch.observer/filing/0001493152-25-009936.json","markdown":"https://secwatch.observer/filing/0001493152-25-009936.md","text":"https://secwatch.observer/filing/0001493152-25-009936.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1433607/000149315225009936/0001493152-25-009936-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1433607/000149315225009936/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T22:14:20.968229+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}